China Journal of Oral and Maxillofacial Surgery ›› 2022, Vol. 20 ›› Issue (4): 413-416.doi: 10.19438/j.cjoms.2022.04.018

• Case Reports • Previous Articles    

Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review

ZHANG Yi-yi1, YANG Yue-yi1, JU Wu-tong2, ZHONG Lai-ping2   

  1. 1. College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200025;
    2. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China
  • Received:2022-02-15 Revised:2022-04-24 Online:2022-07-20 Published:2022-08-02

Abstract: Neoadjuvant therapy is systemic therapy before local treatment in patients with non-distant metastatic malignancies, aiming to reduce tumor load and distant metastasis, increase opportunity of radical resection, and relieve symptoms, et al. In this report, we presented two patients with locally advanced oral squamous cell carcinoma, who were treated with camrelizumab and apatinib as neoadjuvant therapy in Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, and reviewed and discussed the relevant literatures.

Key words: Oral squamous cell carcinoma, Neoadjuvant therapy, Multidisciplinary team

CLC Number: